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Abstract
Background: Some children are prone to recurrent invasive pneumococcal disease (rIPD) and of these, some
respond insufficiently to standard pneumococcal vaccination. Little is known about how to handle these children
and if they benefit from additional vaccination. Here, we present results from a nationwide study of pediatric rIPD
including data on serotype-specific vaccination response to pneumococcal polysaccharide vaccination (PPV23) and
pneumococcal conjugate vaccination (PCV7/13).
Methods: A retrospective, population-based study was conducted using The National Streptococcus pneumoniae
Registry, which contains laboratory-confirmed data from all cases of IPD in Denmark. From January 1980–June 2013
all children aged 0–15 years with rIPD were identified. Clinical data and data on serotype-specific pneumococcal
antibody response were collected. Over the years quantification of pneumococcal antibodies varied from being
presented in arbitrary units (ELISA), in μg/ml (WHO ELISA) and lately in μg/ml based on Luminex technology.
Results: 2482 children were diagnosed with IPD and 75 episodes of rIPD were documented in 59 children. An
underlying disease was documented in 45 (76%) children. Vaccination data were available for 26 children; 11 were
vaccinated solely with PPV23, 8 with a combination of PPV23 + PCV7, 5 with PCV7 and 2 with PCV13. In total, nine
responded to PPV23 vaccination and ten were PPV23 non-responders. Of the 15 PCV vaccinated children, two children
responded subnormal to PCV7. Among PPV23 non-responders, five responded to subsequent PCV vaccination.
Conclusions: In our population-based study of children with rIPD 53% of the children responded insufficiently to
PPV23 vaccination. PPV23 non-responders benefitted from PCV vaccination.
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Background
Invasive pneumococcal disease (IPD) causes significant
morbidity and mortality in children [1]. Primarily chil-
dren with known risk factors experience recurrent IPD
(rIPD). Between 40—92% of children with rIPD have co-
morbidities such as leukemia, cerebrospinal fluid leak or
primary immune deficiency [2–8]. Some children with
rIPD respond insufficiently to pneumococcal vaccination
[9]. Little is known about how to handle these children
and if they benefit from additional vaccination.
The polysaccharide vaccines (PPV14 and later the
PPV23) have been available since the late 1970s. They
are T-cell independent vaccines and therefore not im-
munogenic in children under the age of 2 years, who
suffer the highest burden of disease. Vaccination with
the pneumococcal conjugate vaccines (PCVs) has been
possible since 2000. The conjugation of polysaccharides
to a carrier protein results in a T-cell dependent immune
response and induction of memory cells and thereby the
possibility for a booster response upon subsequent anti-
gen exposure [10–12].
The introduction of conjugate vaccines in childhood
vaccination programmes has had a significant impact on
the morbidity caused by Streptococcus pneumoniae, in-
cluding in Denmark [13, 14]. However, IPD does still
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occur and it is important to protect children at risk of
IPD. Schedules combining PCVs with PPV23 have been
proposed and studied in order to expand disease
protection against serotypes not included in the PCVs
[11, 15, 16], but little is known on vaccination response
in children with rIPD.
In this paper we present results from a 33-year retro-
spective nationwide study of an unselected population of
children with rIPD. We present data on vaccination re-
sponse in 26 children experiencing rIPD. The specific aim
was to quantify the serotype specific vaccination response
to PPV23 and PCV in children experiencing rIPD and to
discuss the clinical management of these children.
Methods
Study design
A retrospective, nationwide analysis was conducted using
The National S. pneumoniae Registry, which contains
laboratory-confirmed data from IPD cases in Denmark dat-
ing back to 1938. Pneumococcal isolates have been submit-
ted from all Departments of Clinical Microbiology in
Denmark on a voluntary basis (since 2007 mandatory [17])
to the National Reference Center at Statens Serum Institut.
It has been estimated that more than 90% of all IPD isolates
are submitted to the reference laboratory [18].
From this registry all children aged 0–15 years with
laboratory-confirmed IPD from January 1980 through
June 2013 were identified and children with recurrent IPD
(rIPD) in the period were included in the study (Fig. 1), as
previously described [7]. Recurrent episodes were defined
as isolation of S. pneumoniae from any normally sterile
site ≥30 days after an initial positive culture or ≤ 30 days if
the recurrent infection was with a new pneumococcal
serotype. Medical records of children experiencing rIPD
were reviewed to identify date and type of pneumococcal
vaccination, date of evaluation of serological pneumococ-
cal antibody (PNA) response. Demographic, clinical and
microbiologic data were obtained.
Serotype specific antibody measurement
Data on PNA response were obtained from the medical
journals and verified in the national serological laboratory
at Statens Serum Institut, Copenhagen. During the study
period from 1980 until 2013, quantification of pneumo-
coccal antibodies varied between different methods
A. Arbitrary units based on a ELISA procedure [19, 20].
B. In μg/ml (WHO/ELISA). This was an update of the
ELISA procedure according to the WHO guidelines
and included adsorption with both CWPS and 22F
polysaccharide [21].
C. Since 2011 in μg/ml based on Luminex technology
using CWPS and 22F adsorbtion as described in
details elsewhere [22–24].
Definition of PPV23 response
PNA measured in arbitrary units
A non-responder was a child over 2 years of age with a
geometric mean antibody titer below 25 units or below
40 units with more than one of the six type specific anti-
body titer below 25 units. A responder was defined as
having a response above the mentioned criteria. More
specific details on the used method, calculation of the
arbitrary units, and definition of a non-responder vs. re-
sponder are outlined in the following studies [19, 20].
PNA measured in μg/ml
A child over 2 years of age with a response (over threshold
1.3 μg/ml) to half or more of the six-twelve tested sero-
types was defined as being a PPV23 responder. Children
with an impaired response to more than half of the tested
serotypes were defined as being non-responders according
to most common international standards [25–27]. In cases
where children were vaccinated with first the PCV and
subsequently the PPV23 the child could only be classified
as a PPV23 reponder after evaluation of the serotypespci-
fic response to non PCV serotypes.
Definition of PCV response
A responder to PCV was defined as a child having a
response of 0.35 μg/ml or more for each of the tested
serotypes [12].
Pneumococcal vaccination in Denmark
In Denmark, routine infant pneumococcal vaccination
with PCV7 (Prevenar 7, Pfizer) was implemented in
2007 [17]. Since 2001 PCV7 was recommended for use
in certain pediatric risk groups [28]. PCV7 was replaced
by the PCV13 from April 2010 [13]. Since the early
1980s a 23-valent polysaccharide vaccine (Pneumova×
23(PPV23), Merck) have been licensed and the vaccine
are used in high-risk children above two years and adult
risk groups [29].
Ethical approval
The Danish Data Protection Authority (Datatilsynet) has
approved usage of the data (j.nr 2013–41-2568).
Results
Epidemiology and clinical characteristics of cohort
During the 33-years study period 2482 children were di-
agnosed with IPD. Among the 2418 children surviving
their first episode of IPD for more than 30 days, 75 epi-
sodes of rIPD were documented in 59 children. Among
the 59 children, 76% had a predisposing underlying dis-
ease at the time of the rIPD, the most common condi-
tions were immune deficiency due to transplantation,
anatomic abnormalities or complement deficiency (more
details described in Ingels et al. [7, 9]).
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Of the 59 children, vaccination data were available for
68% (n: 40) of the cohort; 14 received no vaccination
and 26 children were vaccinated (Fig. 1). Data on
pneumococcal antibody response were available in all
vaccinated children.
Among the 26 children who where vaccinated, five
children were vaccinated solely with PCV7, two children
with PCV13, eight with a combination of PPV23 and
PCV7/13 and eleven of the children were vaccinated
with PPV23. Table 1 presents specific vaccination data.
Vaccination response to PCV7/13
In total, 15 of the children exeriencing rIPD were vacci-
nated with the PCV7 or PCV13. Of these, two were vacci-
nated as a result of the general infant PCV vaccination
program [16] and 13 were offered PCV as part of the rec-
ommendations for vaccination of high-risk children [27].
All except two children (pt 7 and pt. 11) responded suffi-
ciently to all of the tested serotypes (Table 1). Patient 7 ex-
perienced rIPD and septicemia with Kingella kingae in the
first three years of life, but after the age of five no enhanced
susceptibility to infections could be documented. After
three doses of PCV7 he still responded subnormally with a
response to four of seven serotypes (Table 2). Patient 7
mounted a normal response to serotype 6B eventhough this
was the serotype he was infected with twice. In contrast,
immunoglobulins were in normal ranges and functional
antibody response to Diphtheria-, Tetanus-, Haemophilus
influenzae type b- and Polio vaccine were normal. This boy
was a non-responder to PPV23 as well and was subse-
quently diagnosed with specific antibody deficiency toward
pneumococcal polysaccharides (SAD) [25, 29]. Patient 11, a
boy who experienced five times IPD, was diagnosed with a
toll-like receptor (TLR) signaling deficiency [29]. This child
had a subnormal PCV7 response with a response under
threshold in four of the serotypes in spite of repetitive PCV
vaccination (Table 2). The immunoglobulins of this child
were in normal ranges, but responses to Diphtheria, Tet-
anus and Haemophilus influenzae type b vaccine were im-
paired as well.
Vaccination response to PPV23
Overall 19 children were vaccinated with PPV23. Of these,
nine (47%) responded PPV23 and 10 (53%) were
non-responders. Among PPV23 non-responders, five chil-
dren were vaccinated with PCV7/13 at least twice and
they all mounted a PNA response over threshold (pt 6—
10 Table 1).
Comparison between PPV23 responders and
non-responders revealed no differences regarding sex or
age. Among PPV23 non responders, three of 10 had no
known underlying condition at time of vaccination,
thereby fulfilling the criteria of SAD ([29]), whereas in the
PPV23 responding group all children had well defined
underlying diseases such as asplenia congenitalis and
leukemia. Among the six complement deficient children
in our cohort, three responded to PPV23 and three were
PPV23 non-responders (more details are presented in [9]).
Fig. 1 Inclusion of children with recurrent invasive pneumococcal disease
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Serotype specific response
For both the PCV7 and the PPV23 we observed serotypes
where the patients could not mount an acceptable re-
sponse. For the PCV7, children were most likely to re-
spond to 6B, 19 V, 14 and, 19F, whereas antigens to 4, 18C
and 23F in some children did not result in a response over
threshold. For PPV23 we observed a low response for
serotype 1, 7F and 18C (Additional file 1: Table S1).
Discussion
In this nationwide study of pediatric rIPD, we found
that, two children failed to respond acceptably to the
PCV7. Moreover, more than half of the children
vaccinated with PPV23 had a reduced vaccination re-
sponse. The group was heterogenous and no clear differ-
ences were observed regarding background disease
between PPV23 responders and PPV23 non responders.
Our results illustrate the importance of evaluating
pneumococcal antibody response on an individual level
in children at high risk of experiencing IPD. The identi-
fication of vaccine non-responders is important and may
allow optimization of vaccination status and consider-
ation of other prophylactic measures, such as treatment
with replacement immunoglobulin, prophylactic antibi-
otics and information to the parents and the child about
how to handle signs of infection.
Table 1 Vaccination Response of children experiencing repetitive episodes of invasive pneumococcal disease
Patient Underlying disease Localization of Infection (serotypes) Vaccine (s) given Responder (R) / Non Responder (NR)
1 Complement C2 deficiency Bacteremia × 2 (6B/34) PPV23 (NR)
2 Complement C2 deficiency Bacteremia × 2 (12F/4) PPV23 (NR)
3 Syndrome, undefined Bacteremia × 2 (7F/23F) PPV23 multiple (NR)
4 Shunt (Dandy-Walker syndrome) Bacteremia × 2 (19F/19F) PPV23 × 2 (NR)
5 HSCT (MB Gaucher) Bacteremia × 2 (18C/18C) PPV23 (NR)
6 No underlying condition found Bacteremia × 2 (6B/6B) PCV7 × 2, PPV23 PCV7 (R), PPV23 (NR)
7 No underlying condition found Bacteremia × 2 (6B/6B) PCV7 × 3, PPV23 PCV7 (Subnormal (Table 2), PPV23 (NR)
8 No underlying condition found Bacteremia × 2 (6A/24F) PCV13, PPV23 × 2 PCV13 (R), PPV23 (NR)
9 Complement C2 deficiency Bacteremia × 3 (6B/16F/14) PCV/ × 2, PPV23 PCV7 (R), PPV23 (NR)
10 Syndrome with malabsorption Bacteremia × 3 (14/19A/19A) PCV7, PPV23 PCV7 (R), PPV23 (NR)
11 Toll-Like receptor signaling defect Bacteremia × 5 (15C/7/7/38/NTpn) PCV7 × 3 PCV7 (Subnormal) (Table 2)
12 Leukemia Bacteremia × 4 (18C/8/8/8) PCV7 × 2, PPV23 R
13 No underlying condition found Meningitis × 2 (14/6B) PCV7 × 3 R
14 Univentricular heart Bacteremia × 2 (33F/33F) PPV23 R
15 Complement C2 deficiency Meningitis × 2 (4/14) PPV23 x multiple R
16 Klippel Trenaunay syndrome Bacteremia × 3 (6A/24F/24F) PPV23 R
17 Asplenia congenitalis Meningitis × 2 (6B/6A) PPV23 R
18 Complement C2 deficiency Bacteremia × 2 (9 V/NTpn) PCV7 × 2, PPV23 R
19 No underlying condition found Meningitis/bacteremia (19F/1) PCV7 × 2 R
20 Hepatic disease (Biliary atresia) Bacteremia × 2 (9 N/23A) PCV7 × 2 R
21 CNS tumor, chemo treatment Bacteremia × 2 (9 V/1) PCV7 × 2 R
22 HSCT (myelodysplasia) Bacteremia × 2 (6B/6B) PCV23 R
23 Complement C2 deficiency Bacteremia × 2 (6B/38) PPV23 R
24 Asplenia congenitalis Meningitis × 2 (23F/15C) PCV7 × 2, PPV23 R
25 No underlying condition found Bacteremia × 2 (19A/19A) PCV13 R
26 Hepatic disease (Biliary atresia) Bacteremia × 2 (9 N/23A) PCV7 R
HSCT Haematopoietic Stem Cell Transplantation, PCV Pneumococcal conjugate vaccine, PPV Pneumococcal polysaccharide vaccine, NTPn Non typeable
S.pneumococcus, Serotypes in bold are included in the vaccine (s) given to the particular child
Table 2 Subnormal Vaccination Response to PCV7 in two Children with rIPD
Serotype 6B 4 9 V 14 18C 19F 23F
Serotypespecific response (ug/ml) Patient 7 0.80 0.21 0.56 0.63 0.17 0.97 0.34
Patient 11 0.41 0.24 0.12 0.49 0.05 0.42 0.5
Numbers in Cursiva: serotypespecific response below threshold (0.35 μg/ml) (ref 28)
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Most PPV23 non- responders had a known background
disease, however three of the non-responders occurred in
apparently healthy children. Antibody response to poly-
saccharide antigens is impaired in young children less
than two years of age. If this non-responsiveness to poly-
saccharides persist over the year of two it becomes an ab-
normality. In our cohort three apparently normal children
over the age of two failed to respond to PPV23, fulfilling
the criteria of Specific Antibody Deficiency (SAD). Nonre-
sponsiveness to pneumococcal polysaccharides may be
the only detectable immune abnormality or it may be as-
sociated with IgG2 subclass deficiency or other B-cell dis-
turbances [26, 27]. The prevalence of this selective
immunodeficiency is not known, but the condition is a
common finding in some groups of children [25–27].
SAD can be associated with repetitive upper respiratory
tract infections [25], which may lead to invasive disease.
Susceptibility to infections in these children may decrease
over time, although in some children the condition pro-
gresses to Common Variable Immunodeficiency (CVID)
[30, 31], which is the reason that these children may re-
quire long-term follow-up.
We documented two children with a subnormal PCV
response. Hyporesponsiveness to a single or two PCV an-
tigens in children has previously been described [32–35].
It has been suggested that serotype-specific hyporespon-
siveness in apparently healthy children may be a result of
nasopharyngeal carriage of that particular pneumococcal
serotype at the time of vaccination [33]. Moreover it is
wellrecognized that not all serotypes in the PCVs are
equally immunogenic. [12, 34, 36] and that the immune
response can vary according to the number of doses ad-
ministered [36]. A way to handle children lacking an anti-
body response to all PCV serotypes is to revaccinate with
an extra PCV dose, which may lead to a sufficient re-
sponse [37]. A child with a subnormal response for several
PCV serotypes, like in our two patients, is an unusual clin-
ical situation and suggests severe B-cell defect and/or
underlying T-cell dysfunction. [37]. The compromised
vaccination response of the child with TLR deficiency is in
accordance with observations from others [38, 39]. Inter-
estingly, one of our patients who responded subnormally
to PCV experienced two episodes with IPD due to sero-
type 6B episodes but was putatively protected against 6B
according to the serology. This illustrates the complexity
of serological testing and is a reminder that serology is just
a correlate of protection. It can be considered that this
child’s antibodies might be of poor quality however this is
just speculative because we did not have the opportunity
to examine the antibody quality in a functional assay.
The PPV23 respondergroup was heterogenous regard-
ing background disease and included, among others,
three complement C2 deficient children, two children
with congential asplenia, one child with leukemia
(vaccinated with the PPV23 during sustainment therapy)
and one child who had undergone stem cell
transplantation.
In the PCV era it has been a matter of debate if a sup-
plemental booster PPV23 vaccine is beneficial in the
interest of broadening the serotype coverage in children
with a high at risk of IPD or if it makes more sense to
include repeat PCV13 doses. Our results show that at
least in some high risk children PPV23 provides a good
response, however the response is individual and some-
what inpredictable.
Further, it must be kept in mind that serotype-specific
correlates of protection are not necessarily adequate to
predict the level of clinical protection in individuals. We
do, nevertheless, on the basis of our findings and others
[40–43] find it beneficial to recommend PPV23 vaccin-
ation as a supplement to primary PCV vaccination.
Children experiencing rIPD are a heterogenous group
and may respond insufficiently to PPV23 vaccination,
therefore each child should probably be assessed indi-
vidually with measurement of PNA pre- and post
immunization to tailor the best programme.
A limitation of our study is the retrospective design. A
prospective study adressing pneumococccal vaccine
response in children with recurrent IPD could in more
detail adress the specific response after and before vaccin-
ation and compare different strategies concerning revac-
cination. Moreover, due to the long time span of the
study, the children in our cohort were exposed to different
pneumococcal vaccine regimes for high risk children,
which makes it difficult to compare the children and ex-
trapolate the results directy to high risk children in 2016.
Also we did not have the possibility to measure the opso-
nophagocytic activity of the antibodies which could have
further illucidate the functional vaccine response.
We do, however, find the results important. This Danish
cohort of children with rIPD is populationbased and one
of the largest known cohorts to date. To our knowledge, a
study of vaccination response of an unselected cohort of
children with rIPD has not previously been carried out.
Conclusion
In conclusion, we document that impaired vaccination re-
sponse to PPV23 is a frequent phenomenon in this clinical
narrow group of children with rIPD, while the phenomen
occurred more rarely with PCV. This implies that vaccin-
ation and vaccination response children with underlying
conditions should be assessed on an individual basis.
Optimal pneumococcal vaccination of risk groups with
combination regimes of vaccines to broaden serotype
coverage seems rational. Consequently, it will be of im-
portance to continuously evaluate the benefits of combin-
ation vaccines in different subpopulations of immune
deficient children in the future, also in prospective studies.
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Additional file
Additional file 1: Table S1. Serotype specific vaccination response. The
table contains the available rawdata concerning the serotype specific
concentrations from all serological tests. Moreover the table includes
data concerning time of vaccination. (DOCX 25 kb)
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